HTR3A
ENSG00000166736
Target class
Ion channel
Chromosome
11
Approved drugs
13
Clinical candidates (approved and in development)
21
- Approved drugs
- 13
- Clinical candidates (approved and in development)
- 21
- Chemical probe available
- Yes
- Target name
- HTR3A
- Gene name
- 5-hydroxytryptamine receptor 3A
- Gene symbol
- HTR3A
- Previous gene symbols
- HTR3
- Protein name
- 5-hydroxytryptamine receptor 3A (5-HT3-A) (5-HT3A) (5-hydroxytryptamine receptor 3) (5-HT-3) (5-HT3R) (Serotonin receptor 3A) (Serotonin-gated ion channel receptor)
- 5-HT3R
- 5-HT3A
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, ionotropic
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 6
- Highest tissue expression
- 2.82
- Tissue specificity (Gini)
- 0.717
- Tissue specificity (tau)
- 0.876
- KEGG gene identifiers
- hsa:3359
- Reactome pathways
- R-HSA-112314
- Protein interaction confidence
- 0.794105
- Protein interaction partners
- 38
- End position
- 113990313
- Start position
- 113975075
- Chromosome
- 11
- Strand
- Forward
- Postsynaptic cell membrane
- Multi-pass membrane protein . Cell membrane
- Multi-pass membrane protein .
Publication evidence
- PubMed 9950429
- Tissue specificity (tau)
- 0.875753
- Expression inequality (Gini)
- 0.716664
Expression in transcripts per million
- Colon - Sigmoid
- 2.82
- Brain - Caudate (basal ganglia)
- 2.42
- Small Intestine - Terminal Ileum
- 2.05
- Minor Salivary Gland
- 1.6
- Colon - Transverse
- 1.38
Expression in transcripts per million
- Colon - Sigmoid2.82
- Brain - Caudate (basal ganglia)2.42
- Small Intestine - Terminal Ileum2.05
- Minor Salivary Gland1.6
- Colon - Transverse1.38
- Brain - Nucleus accumbens (basal ganglia)1.21
- Brain - Hippocampus0.97
- Brain - Putamen (basal ganglia)0.89
- Brain - Anterior cingulate cortex (BA24)0.85
- Esophagus - Muscularis0.82
- Brain - Amygdala0.72
- Pancreas0.71
- Brain - Cortex0.67
- Skin - Sun Exposed (Lower leg)0.63
- Spleen0.61
- Brain - Frontal Cortex (BA9)0.55
- Stomach0.52
- Esophagus - Gastroesophageal Junction0.37
- Testis0.33
- Bladder0.13
- Skin - Not Sun Exposed (Suprapubic)0.11
- Esophagus - Mucosa0.09
- Fallopian Tube0.09
- Vagina0.07
- Cervix - Endocervix0.06
And 29 more, listed on the interactive page.
- GO:0007210
- GO:0055085
- GO:0140227
- GO:0005886
- GO:0032154
- GO:1904602
- GO:0005515
- GO:0022850
- GO:0051378
decreased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased memory
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264vomiting
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: vomiting
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased gastrointestinal transit
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased gastrointestinal transit
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264constipation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: constipation
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264hard stool
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: hard stool
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264drug abuse/dependence
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drug abuse/dependence
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased inflammation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased inflammation
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased blood pressure
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264abdominal distension
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: abdominal distension
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264dizziness
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: dizziness
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased gastric emptying
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased gastric emptying
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased heart rate
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264ischemic colitis
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: ischemic colitis
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased anxiety
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased anxiety
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased memory
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased memory
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased gastrointestinal transit
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased gastrointestinal transit
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264apnea
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: apnea
- central nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264
gastric emptying
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: gastric emptying
- endocrine
- gastrointestinal
PubMed 23197038constipation
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: constipation
- endocrine
- gastrointestinal
PubMed 23197038possible increased heart rate
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: possible increased heart rate
- endocrine
- gastrointestinal
PubMed 23197038receptor binding
Studies
- biochemical: NVS_LGIC_h5HT3, is one of one assay component(s) measured or calculated from the NVS_LGIC_h5HT3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourcedizziness
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: dizziness
- endocrine
- gastrointestinal
PubMed 23197038emesis
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: emesis
- endocrine
- gastrointestinal
PubMed 23197038hyperglycaemia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: hyperglycaemia
- endocrine
- gastrointestinal
PubMed 23197038
Related records
Trials (1,122)
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- "THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"
- 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
- 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
- 5-HT3 Antagonists (Antiemetics) and Cardiac Safety
- 5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)
- 5-HT3 Receptor Antagonist and Respiratory Drive in Patients With ARDS
- 5HT3 Antagonism and Auditory Gating in Schizophrenia
- 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
- A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder
- A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)
- A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets
- A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)
- A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes
- A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting
- A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)
- A Cohort Study Evaluating the Efficacy of PO Magnesium in the Treatment of Acute Traumatic Brain Injury in Adolescents
- A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron
- A Comparative Evaluation of Mosapride Versus Metoclopramide for Enteral Feeding Intolerance in Critically Ill Patients
- A COMPARATIVE STUDY BETWEEN 1MG AND 3 MG OF GRANISETRON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN STRABISMUS OPHTHALMIC SURGERIES DURING GENERAL ANESTHESIA
Drugs (44)
- Alosetron Serotonin 3a (5-HT3a) receptor antagonist
- Alosetron hydrochloride Serotonin 3a (5-HT3a) receptor antagonist
- Amisulpride Serotonin (5-HT) receptor antagonist
- Azasetron
- AZD0328
- Cilansetron Serotonin 3 (5-HT3) receptor antagonist
- Cilansetron hydrochloride Serotonin 3 (5-HT3) receptor antagonist
- Clothiapine Serotonin 3 (5-HT3) receptor antagonist
- Cocaine
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- Diltiazem
- Dolasetron Serotonin 3a (5-HT3a) receptor antagonist
- Dolasetron mesylate Serotonin 3a (5-HT3a) receptor antagonist
- Facinicline Serotonin 3 (5-HT3) receptor antagonist
- Facinicline hydrochloride Serotonin 3 (5-HT3) receptor antagonist
- Granisetron Serotonin 3a (5-HT3a) receptor antagonist
- Granisetron hydrochloride Serotonin 3a (5-HT3a) receptor antagonist
- Indisetron
- Metoclopramide Serotonin 3a (5-HT3a) receptor antagonist